aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT(TM) Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Stock Information for aTyr Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About aTyr Pharma Inc.

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT(TM) Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
 aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.